CHICAGO, Ill. (Reuters) — Shareholders of U.S. seed and agrochemical company Mon-santo Co. approved the company’s US$66 billion acquisition by Bayer AG Dec. 13, a deal that still requires regulatory approval if it is to close as expected in late 2017.
Increased research and development spending by the combined companies and plans to develop a global seed and biotechnology hub in St. Louis, Missouri, fuel hopes that regulators will not block the deal, which was agreed upon in September, Monsanto chief executive officer Hugh Grant said.
“I think those augur well for the deal,” he said.
Read Also
Agri-business and farms front and centre for Alberta’s Open Farm Days
Open Farm Days continues to enjoy success in its 14th year running, as Alberta farms and agri-businesses were showcased to increase awareness on how food gets to the dinner plate.
If the deal closes, it will create a company commanding more than a quarter of the combined world market for seed and pesticides in the fast-consolidating farm supplies industry.
Uncertainty about whether U.S. President-elect Donald Trump would stand in the way of large mergers after taking office in January has clouded the outlook of some deals.
Trump vowed during his campaign to block AT&T Inc.’s purchase of Time Warner Inc. and look to break up Comcast Corp.’s deal to buy NBC Universal, citing too much concentration of power.
The president does not directly decide if a merger is illegal under antitrust law. That is done by the U.S. justice department or the Federal Trade Commission, which divide up the work of assessing mergers.
If one of the agencies decides to stop a deal, it must convince a judge to agree.
Grant said he has not met with Trump or any of his transition team and did not elaborate on how the company was working to secure the deal.
The acquisition came after a string of large mergers that have roiled the agribusiness sector in the last year or so, including ChemChina’s purchase of Swiss chemical company Syngenta AG and a merger of Dow Chemical and DuPont.
DuPont CEO Ed Breen said the incoming Trump administration is not likely to affect his company’s merger with Dow Chemical.
